Cargando…
Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study
BACKGROUND: Everolimus (EVE) is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, and it is approved for the treatment of advanced breast cancer (ABC). However, there is still little real-world data on using EVE in Chinese breast cancer patients. We retrospectively analyzed real-worl...
Autores principales: | Shen, Xia-Bo, Li, Guang-Liang, Zheng, Ya-Bing, Chen, Zhan-Hong, Cao, Wen-Ming, Wang, Xiao-Jia, Shao, Xi-Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422157/ https://www.ncbi.nlm.nih.gov/pubmed/34532471 http://dx.doi.org/10.21037/atm-21-3840 |
Ejemplares similares
-
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
por: Gong, Chengcheng, et al.
Publicado: (2017) -
Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus
por: Duan, Fangfang, et al.
Publicado: (2021) -
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020) -
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
por: Le, Vivian, et al.
Publicado: (2021) -
Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)